Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | IL6 | P05231 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206648 | 1.00 | TLR7 (0.38) | TLR7ADORA1ADORA2APNPADRB2 | |
| SCHEMBL21324597 | 0.87 | PNP (0.41) | TLR7PNPADRB2HTR1AIL6 | |
| SCHEMBL20202019 | 0.87 | PNP (0.41) | TLR7PNPADRB2HTR1AIL6 | |
| SCHEMBL20202017 | 0.83 | PNP (0.38) | PNP | |
| SCHEMBL20206650 | 0.82 | PNP (0.36) | PNP | |
| SCHEMBL20202021 | 0.82 | PNP (0.36) | PNP | |
| SCHEMBL24438127 | 0.71 | MC1R (0.50) | ADRB2HTR1ABCHE | |
| SCHEMBL20202014 | 0.69 | PNP (0.37) | PNP | |
| SCHEMBL22919730 | 0.69 | TDP1 (0.51) | ADRB2HTR1ABCHECA12CA1 | |
| SCHEMBL24916653 | 0.69 | TDP1 (0.51) | ADRB2HTR1ABCHECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148764-A1 | ENZYMATIC MODIFICATION OF NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148764-A1 | ENZYMATIC MODIFICATION OF NUCLEIC ACIDS | RNGTT, UNG, RNASEL | TLR7 4216/4885ADORA1 2563/4885ADORA2A 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.